title: Impact of therapeutic changes on renal graft survival with posttransplant glomerulonephritis.
abstract: BACKGROUND
  Posttransplant glomerulonephritis (GN) is the third cause of graft loss after 1 year of transplant follow-up; few approaches have been efficient in reversing this outcome. The aim of this study was to evaluate whether the modification of the immunosuppressive therapy for treating posttransplant GN had an impact on allograft survival.
  
  
  METHODS
  Forty-nine patients who underwent renal transplantation and developed posttransplant GN were divided into two groups: group 1, 22 patients with modified immunosuppressive treatment (72.3%, pulse of methylprednisolone; 13.6%, high-dose oral corticosteroid), and group 2, where it was maintained. Additionally, the impact of the concomitant use of drugs that promote the renin-angiotensin-aldosterone system blockade (RAASB) was analyzed in terms of graft survival.
  
  
  RESULTS
  We established the diagnosis of GN at 17.9 months (range, 0.57 to 153.4) after transplantation, when serum creatinine (Cr) was 2.2 mg/dL (range, 0.8 to 12.5) and proteinuria 3.2 g/L (range, 0.2 to 24.2). Graft survivals at 1 and 3 years after diagnosis were 69.2% and 52.9%, respectively. The patients of group 1 showed a lower prevalence of graft loss (27.2% versus 48.1%, P = .40) and better survival at the end of 1 year (73.2% versus 60.4%) and 3 years (62.5% versus 38.0%, P = .26), but the differences were not significant. RAASB showed a positive impact on survival at the end of 3 years in both groups: for group 1, 83.8% with RAASB, 41.4% without RAASB; and for group 2, 75% with RAASB and 14.8% without RAASB (P < .001).
  
  
  CONCLUSIONS
  Although treatment of posttransplant GN with modification of immunosuppression seemed to improve graft survival in the first 3 years after diagnosis, RAASB improved this effect.
authors.affiliation: Laboratory of Clinical and Experimental Immunology, Universidade Federal de São Paulo, UNIFESP, São Paulo, Brazil.
authors.forename: L R
authors.initials: LR
authors.lastname: Requião-Moura
authors.forename: G
authors.initials: G
authors.lastname: Mastroianni-Kirsztajn
authors.forename: G T
authors.initials: GT
authors.lastname: Moscoso-Solorzano
authors.forename: M F
authors.initials: MF
authors.lastname: Franco
authors.forename: K S
authors.initials: KS
authors.lastname: Ozaki
authors.forename: A
authors.initials: A
authors.lastname: Pacheco-Silva
authors.forename: N O S
authors.initials: NO
authors.lastname: Câmara
mesh_terms: D000328:Adult; D005260:Female; D005921:Glomerulonephritis / Q000453:epidemiology*; D006085:Graft Survival / Q000502:physiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000502:physiology*; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000145:classification / Q000453:epidemiology; D011507:Proteinuria / Q000453:epidemiology
chemical_list: D007166:Immunosuppressive Agents